



SENDERRA

Specialty Pharmacy

3712 E. Plano Parkway, Ste. 200
Plano, TX 75074

This prescription form is to be sent & received via fax

**Dermatology Injectable
Enrollment Form E-L**

**Physician Offices Call:
855-460-7928**

Fax: 888-777-5645

Prescriber:

NPI:

Supervising Physician:

NPI:

Address:

Tax ID:

Phone:

Fax:

Contact:

PATIENT INFORMATION

Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____ / ____ / ____	SS#: ____ - ____ - ____
Street:	City:	State: ____	ZIP: ____
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____


PRESCRIPTION

Has the patient received a loading dose/starter kit? Yes Start Date: ____ / ____ / ____ No SHIP TO: Patient's Home Doctor's Office Other: _____

Drug		Directions & Quantity	Refills
Enbrel®	<input type="checkbox"/> SureClick® Pen <input type="checkbox"/> Mini® with AutoTouch® <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 50 mg SQ twice weekly (72-96 hours apart) for 3 months (Quantity: 8 with 2 refills) <input type="checkbox"/> MAINTENANCE: Inject 50 mg SQ weekly (Quantity: 4)	
Humira® Citrate Free	<input type="checkbox"/> 40 mg Pen <input type="checkbox"/> 40 mg Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (Quantity: QS) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)	
Ilumya®	<input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 100 mg SQ at weeks 0 & 4 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 100 mg SQ every 12 weeks (Quantity: 1)	

MEDICAL INFORMATION

*****PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY*****

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	
<input type="checkbox"/> Methotrexate	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	Affected Areas
<input type="checkbox"/> Soriatane	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	<input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands
<input type="checkbox"/> Clobetasol	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	<input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: _____
<input type="checkbox"/> Humira	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	BSA % PASI Score: _____
<input type="checkbox"/> Enbrel	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
PHOTOTHERAPY		Tried & Failed (Duration):	Not Tolerated:	Contraindication:
<input type="checkbox"/> UVA /UVB		<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Patient cannot afford		<input type="checkbox"/> Photosensitivity	<input type="checkbox"/> Risk of Skin Cancer	<input type="checkbox"/> Distance from Office
<input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis)		<input type="checkbox"/> Other: _____		
Date of Diagnosis: ____ / ____ / ____				

Active TB is ruled out: Yes No Date: ____ / ____ / ____ Hep B ruled out/treated: Yes No Date: ____ / ____ / ____

Additional Clinical Information:

American Academy of Dermatology Consensus Statement on Psoriasis Therapies

Psoriasis is covering greater than 10% of body surface area Psoriasis is on palms, soles, head and neck, or genitalia Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
 Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships

INJECTION TRAINING

Patient has received pen and injection training Physician's office to provide injection training Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber:

Date: ____ / ____ / ____

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.